<DOC>
	<DOCNO>NCT01379534</DOCNO>
	<brief_summary>This prospective , multi-center , open-label , single-arm , non-randomized , Phase II study evaluate efficacy safety TKI258 second-line therapy patient either FGFR2 mutate wild-type advanced and/or metastatic endometrial cancer .</brief_summary>
	<brief_title>A Phase II Study Evaluate Efficacy TKI258 Treatment Patients With FGFR2 Mutated Wild-type Advanced and/or Metastatic Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Patients histologically confirm diagnosis advance and/or metastatic endometrial cancer available tissue specimen ( either archival tissue fix fresh biopsy ) Female patient ≥ 18 year old Documented radiologically confirm progression disease prior firstline treatment evidence progressive disease ECOG ( Eastern Cooperative Oncology Group ) performance status ≤ 2 At least one measurable lesion per RECIST Previous treatment FGFR inhibitor More one line treatment advance metastatic disease Patients uterine sarcoma , adenosarcoma , malignant Mullerian tumor Patients isolated recurrence ( vaginal , pelvic , paraaortic ) potentially curative radiation therapy surgery Known central nervous system ( CNS ) metastases Malignancy within 3 year study enrollment Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Solid tumor ,</keyword>
	<keyword>advanced endometrial cancer ,</keyword>
	<keyword>Endometrial Cancer ,</keyword>
	<keyword>Second-line treatment ,</keyword>
	<keyword>VEGF ,</keyword>
	<keyword>Neoplasms ,</keyword>
	<keyword>Endometrial Neoplasms ,</keyword>
	<keyword>Uterine Neoplasms ,</keyword>
	<keyword>Female Genital Neoplasms ,</keyword>
	<keyword>Cancer ,</keyword>
	<keyword>Carcinoma ,</keyword>
	<keyword>Uterine Diseases ,</keyword>
	<keyword>Female Genital Diseases ,</keyword>
	<keyword>Tumors ,</keyword>
	<keyword>Oral Administration ,</keyword>
	<keyword>Capsules ,</keyword>
	<keyword>Tablets ,</keyword>
	<keyword>CHIR258 ,</keyword>
	<keyword>CHIR-258 ,</keyword>
	<keyword>CHIR 258 ,</keyword>
	<keyword>TKI258 ,</keyword>
	<keyword>TKI-258 ,</keyword>
	<keyword>TKI 258</keyword>
</DOC>